The approval of eflornithine (brand name Iwilfin) for pediatric high-risk neuroblastoma offers an interesting example of how the FDA evaluates single-arm trials supported by external control arms (ECAs). External controls are increasingly common in oncology and rare disease drug development, but they remain a source of careful regulatory scrutiny. In this case, the FDA’s assessment… Continue reading Regulatory Insights from FDA Review of the External Control Arm in a Pediatric Rare Disease Trial
Category: Clinical Research
The Expanding Role of Epidemiology in Modern Real-World Data Research
When observational retrospective research began to be used more systematically more than twenty years ago, the real-world data (RWD) landscape was relatively simpler. Not necessarily easier, but simpler. A limited number of large administrative and clinical databases dominated the field. Claims databases, national registries and a handful of electronic medical record (EMR) sources were directing… Continue reading The Expanding Role of Epidemiology in Modern Real-World Data Research
EHDS Section 60: The Illusion of Neutral Data Sharing?
Reading the EHDS regulation carefully, and in particular Section 60, leaves a sense of discomfort that is not really about legal drafting, but about how knowledge is produced and legitimized. The text is cautious, layered with safeguards, and repeatedly reassures the reader that intellectual property, trade secrets, and commercial confidentiality remain protected. And yet, between… Continue reading EHDS Section 60: The Illusion of Neutral Data Sharing?
Do Pharma Still Need Large CROs for RWD Studies?
In the traditional model of real-world evidence (RWE) generation, sponsors relied almost automatically on contract research organizations (CROs) to manage observational studies end to end. That model made sense when data were fragmented, technology limited, and sponsors lacked internal capacity. Today, the landscape is very different. Data networks are richer, analytical platforms are significantly more… Continue reading Do Pharma Still Need Large CROs for RWD Studies?
The Health Data Lab in Germany: A Country Initiative with a Central Role in Health Data Science
What the Health Data Lab Is and How It Works In recent years, Germany has taken important steps toward building a national infrastructure for health data that can support research, planning, and policy. One of the most ambitious initiatives in this direction is the Health Data Lab (Gesundheitsdatenlabor, HDL), managed by the Federal Institute… Continue reading The Health Data Lab in Germany: A Country Initiative with a Central Role in Health Data Science